Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Click Here to

Protocol-Ineligible Patients With Metastatic Renal Cell Carcinoma Fare Worse Than Those Eligible for Clinical Trials

TON - MARCH 2012 VOL 5, NO 2 published on April 10, 2012 in In the News

Patients with metastatic renal cell carcinoma (mRCC) who do not meet eligibility criteria for clinical trials have worse outcomes on targeted therapy compared with eligible patients. In fact, extrapolating results of clinical trials to ineligible patients leads to inferior response rates (RRs), progression-free survival (PFS), and overall survival (OS). 

“Many patients in everyday practice do not meet eligibility for clinical trials, yet they receive the same targeted therapies as those in clinical trials. Our study shows that ineligible patients have worse outcomes and 1.5 times greater risk of death on the same therapies compared with eligible patients. These findings suggest that these discrepancies should be taken into account when we consider using protocol therapies in protocol-ineligible patients. We need to temper our enthusiasm,” said lead author Daniel Yick Chin Heng, MD, Tom Baker Cancer Centre, University of Calgary, Alberta, Canada. Heng presented the study results at the 2012 ASCO Genitourinary Cancers Symposium. 

The study included 894 ineligible patients and 1182 eligible patients with mRCC consecutively treated with VEGF-targeted therapy at 17 international cancer centers. Patients were deemed ineligible retrospectively according to common exclusion criteria for clinical trials. All other patients were assumed to be eligible. 

Patients received a variety of anti-VEGF tyrosine kinase inhibitors, including sunitinib, sorafenib, bevacizumab, pazopanib, and axitinib. The most common exclusion criteria were Karnofsky performance status <70% (13.4%), nonclear cell histology (11.2%), brain metastasis (8.3%), and hemoglobin 9 g/dL (7.4%). Patients in the ineligible group were much more likely to be poor risk, and fewer had undergone nephrectomy compared with eligible patients. 

Overall response rate was 27%. RR was 34% in favorable-risk patients, 28% in intermediate-risk patients, and 19% in poor-risk patients. RRs were uniformly lower in ineligible patients than eligible patients for every risk category. 

Median PFS was 8.6 months for eligible patients and 5.2 for ineligible patients (P <.0001); median PFS when these drugs were used as second-line therapy was 4.4 months and 3.2 months, respectively (P = .0074). Median OS was 28.8 months versus 14.5 months, respectively (P <.0001). “Specific trials should be undertaken to address the needs of protocol-ineligible patients and assess overall survival,” he said.

Related Items
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 18, 2020 in Health Policy, In the News
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
Mixed Findings in Annual Cancer Statistics Report
Web Exclusives published on January 20, 2020 in In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Recap of FDA Drug Approvals in 2019
Web Exclusives published on January 7, 2020 in FDA Updates, In the News
FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
Web Exclusives published on December 16, 2019 in In the News, Pediatric Cancer
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Sarcoma
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
November 25, 2019 – Oncology News & Updates
Web Exclusives published on November 25, 2019 in FDA Updates, In the News, Leukemia, Lung Cancer, Lymphoma
Last modified: September 9, 2019